Does Independence Blue Cross Cover Wegovy?

No. Independence Blue Cross excluded weight-loss GLP-1 coverage — including Wegovy for weight loss — effective January 1, 2025 on fully insured group and individual plans. This is a benefit design exclusion, not a medical-necessity denial, so a standard PA appeal will not succeed. Self-funded employer groups may have opted in separately — ask HR whether your plan is fully insured or self-funded. The only insured routes remaining are the cardiovascular indication (for members with established CVD) and diabetes coverage.

An appeal based on medical necessity will not succeed if your plan has excluded weight-loss GLP-1s as a benefit design decision — these two types of denial are different. A medical-necessity denial is appealable if the insurer applied criteria incorrectly; a benefit exclusion means the drug is simply not in your plan's covered benefits at all. If you believe your plan should include the benefit, ask HR whether your employer could add anti-obesity drug coverage in the next open enrollment cycle.

Yes. The cardiovascular risk-reduction indication — FDA-approved for adults with established CVD (prior heart attack, stroke, or symptomatic PAD) who are overweight or obese — may be covered with prior authorization on applicable Independence plans, including Medicare plans. This is a separate FDA indication from weight management and survives the weight-loss exclusion. Contact Independence member services or your prescriber to confirm PA criteria for the CV indication on your specific plan.

No. Medicare Part D cannot cover Wegovy for weight loss by statute — this is a federal prohibition, not an Independence policy. Independence Medicare Advantage plans can cover Wegovy for the cardiovascular indication with PA. The Medicare GLP-1 Bridge (launching July 1, 2026) provides weight-loss access at $50/month outside Part D for eligible beneficiaries; eligibility requires BMI 35 or higher, or BMI 30 with heart failure or uncontrolled hypertension or CKD, or BMI 27 with prediabetes, prior MI, prior stroke, or symptomatic PAD.

Before January 1, 2025, Independence Blue Cross covered anti-obesity medications including Wegovy with prior authorization for eligible commercial members. The exclusion took effect at the start of 2025 due to rising GLP-1 drug costs across the industry. Members who were mid-therapy may have received transition periods — contact Independence member services for historical enrollment questions. Going forward, only the CV and diabetes indications are covered on fully insured and individual plans.